Siglec-15-targeting therapy increases bone mass in rats without impairing skeletal growth

The treatment of juvenile osteoporosis has not been established due to a lack of data regarding the efficacy and adverse effects of therapeutic agents. The possible adverse effects of the long-term use of antiresorptive therapies on skeletal growth in children is of particular concern. Sialic acid-binding immunoglobulin-like lectin 15 (Siglec-15) is an immunoreceptor that regulates osteoclast development and bone resorption, and its deficiency suppresses bone remodeling in the secondary spongiosa, but not in the primary spongiosa, due to a compensatory mechanism of osteoclastogenesis.

Source: Bone - August 1, 2018 Category: Orthopaedics Authors: Dai Sato, Masahiko Takahata, Masahiro Ota, Chie Fukuda, Eisuke Tsuda, Tomohiro Shimizu, Akiko Okada, Yoshiharu Hiruma, Hiroki Hamano, Shigeto Hiratsuka, Ryo Fujita, Norio Amizuka, Tomoka Hasegawa, Norimasa Iwasaki Tags: Full Length Article Source Type: research